Influence of TNF-alpha on the efficacy of anemia correction in patients with lymphoproliferative disorders

   In this article mechanisms of anaemia development in patients with lymphatic tissue malignant diseases are presented. Therapy efficacy of erythropoiesis-stimulating agents (EPO) in patients with lymphoproliferative disorders and anaemia (n = 21) is studied. Study group included patients with a chronic lymphoid leukemia (n = 5), indolent lymphomas (n = 7) and multiple myeloma (n = 9). Patients were 49–80 years of age (63.6 ± 8.2 years). The positive response to EPO therapy was considered if hemoglobin level increased on 20 g/l or its rising to 120 g/l. With given therapy hemoglobin level was increased from 86.8 ± 18.5 g/l to 111.4 ± 26.5 g/l (p < 0.001). EPO therapy efficacy was 61.9 % for total group of patients. Importance of TNF-alpha detection as the prognosis factor of EPO therapy efficacy was studied. Patients with low level of TNF-alpha (less than 15 pg/ml) achieved the positive response in 92.9 %, with a high level of TNF-alpha (more than 15 pg/ml) – the positive response was not observed. Inversely proportional correlation between initial TNF-alpha level and therapy response has been established (r = -0.487; p < 0.03; n = 21). Thus, detection of TNF-alpha level in patients with lymphoproliferative disorders before EPO therapy allows to predict therapy response with high degree of significance.

1. Kyle R. A. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50: 29–40.

2. Ludwig H., Rai K., Blade J. et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002; 3 (3): 121–30.

3. Moulet L., Salles G., Ketterer N. et al. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol 1998; 9 (10): 1109–15.

4. Straus D. J. Epoetin alfa therapy for parameters with hematologic malignancies and mild anemia. Clin Lymphoma 2003; 4 (Suppl 1): 13–7.

5. Богданов А. Н. Диагностика и дифференциальная диагностика анемий / А. Н. Богданов, А. А. Новик // Вестн. Гематол. – 2005. – Т. 1. – 4: 63–70.

6. Hudis C. A., van Belle S., Chang J., Muenstedt K. rHuEPO and treatment outcomes: the clinical experience. Oncologist 2004; 9 (Suppl. 5): 55–69.

7. Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma 2003; 4 (Suppl 1): 23–9.

8. Гусева С. А. Анемии при хронических и опухолевых заболеваниях / С. А. Гусева // Укр. журн. гематол. и трансфуз. – 2003. – 4: 32–8.

9. Rizzo J. Douglas, Lichtin Alan E., Woolf Steven H. et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100 (7): 2303–20.

10. Мулле И. Частота и значение анемии у больных с неходжкинскими лимфомами / И. Мулле [и др.] // Анемия у онкол. больных. – 2002. – 1: 19–21.

11. Littlewood T., Mandelli F. The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol 2002; 29 (3 (Suppl 8)): 40–4.

12. Romanenko N. A., Rozanova O. E., Glazanova T. V., Abdulkadyrov K. M. A study of the influence of TNF-alpha on the efficacy of treatment with recombinant erythropoietin in patients with lymphoproliferative disorders. Haematologica 2010; 95 (S2): 354–5.

13. Pierce C. N., Larson D. F. Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device. Perfusion 2005; 20 (2): 83–90.

14. Птушкин В. В. Дискуссионные вопросы применения эритропоэтинов в лечении анемии у пациентов с опухолевыми заболеваниями / В. В. Птушкин // Онкогематол. – 2007. – 2: 31–6.

15. Jonson J. Y., Waddelow T. A., Caro J. et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989; 74: 130–8.

16. Lombard M., Chua E., O’Toole P. Regulation of intestinal non-haem iron absorbtion. Gut 1997; 40: 435–9.

17. Moldawer L. L., Marano M. A., Wei H. et al. Cachectin/ tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989; 3: 1637–43.

18. Романенко Н. А. Лечение анемии у больных с лимфопролиферативными заболеваниями рекомбинантным эпоэтином α / Н. А. Романенко, К. М. Абдулкадыров // Клин. онкогематол. – 2008. – 1 (3): 233–7.

19. Сараева Н. О. Механизмы развития анемии при гемобластозах / Н. О. Сараева // Гематол. и трансфуз. – 2007. – Т. 52 (1): 31–7.

20. Ludwig H., Pohl G., Osterborg A. Anemia in multiple myeloma. Clin Adv Hematol Oncol 2004; 2 (4): 233–41.

21. Romanenko N. A., Abdulkadyrov K. M. Study of effectiveness recombinant human erythropoietin in lymphoproliferative disorders patients with anemia. Haematologica 2010; 95 (Suppl 2): 190.

22. Бессмельцев С. С. Эритропоэтины в лечении анемии у пациентов с гематологическими и солидными опухолями / С. С. Бессмельцев, Н. А. Романенко, К. М. Абдулкадыров // Вестн. Гематол. – 2010. – 6 (2): 124–35.

23. Романенко Н. А. Коррекция и лечение анемии у больных с гемобластозами эритроцитсодержащими компонентами крови и препаратами рекомбинантного эритропоэтина / Н. А. Романенко // Вестн. Гематол. – 2007. – 3 (4): 46–54.

24. Osterborg A., Brandberg Y., Molostova V. et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002; 20 (10): 2486–94.

25. Гусева С. А. Коррекция анемии рекомбинантным эритропоэтином-альфа у больных миеломной болезнью / С. А. Гусева, Е. В. Дарушин, Я. П. Гончаров // Укр. журн. гематол и трансфуз. – 2003. – 5: 11–6.

26. Henry D. H. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies. Drugs 2007; 67 (2): 175–94.

27. Cazzola M., Messinger D., Battistel V. et al. Recombinant human erythropoietin in anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: Dose finding and identification of predictors of respons. Blood 1995; 86: 4446–53.

28. Henry D. H. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 1994; 8: 961–74.

29. Ludwig H., Leitgeb C., Fritz E. et al. Erythropoietin treatment of chronic anemia of cancer. Europ J Cancer 1993; 29A (Suppl 2): 8–12.

30. Musto P., Falcone A. D’Arena et al. Clinical results of recombinant human erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis. Eur J Haematol 1997; 58: 314–9.

31. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34 (3 Suppl 2): 13–9.

32. Straus D. J., Testa M. A., Sarokhan B. J. et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 2006; 107 (8): 1909–17.

33. Pujade-Lauraine E., Topham C. Onceweekly treatment of anemia in patients with cancer: a comparative review of epoetins. Oncology 2005; 68 (2–3): 122–9.

34. De La Motte Rouge T., Schneider M. Anemia in lymphoma. Bull Cancer 2005; 92 (5): 429–31.

35. Shehata N., Walker I., Meyer R. et al. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review. Ann Hematol 2008; 87 (12): 961–73.

36. Cazzola M., Beguin Y., Kloczko J. et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003; 122 (3): 386–93.

37. Takagi M., Migamoto Y., Kosaka M. et al. Clinical significance of serum erythropoietin levels in patients with multiple myeloma. Rinsho Ketsueki 1992; 33: 1151–7.

38. Cazzola M., Messinger D., Battistel V. et al. Recombinant human erythropoietin in anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: Dose finding and identification of predictors of respons. Blood 1997; 90: 358a.

39. Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 1998; 25 (3 Suppl 7): 27–34.

40. Katodritou E., Terpos E., Zervas K. et al. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol 2007; 86 (5): 369–76.

41. Roodman G. D., Johnson R. A., Clibon U. Tumor necrosis factor alpha and the anemia of chronic disease: effects of chronic exposure to TNF on erythropoiesis in vivo. Adv Exp Med Biol 1989; 271: 185–96.

42. Kato A., Odamaki M., Takita T. et al. High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 2001; 16 (9): 1838–44.

43. Stasi R., Brunetti M., Bussa S. et al. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietinin patients with myelodysplastic syndrome. Clinn Lab Haematol 1997; 19: 197–201.